Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Bevacizumab + Niraparib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Bevacizumab||Avastin||VEGF Antibody 11 VEGFR Inhibitor (Pan) 36||Avastin (bevacizumab) is a monoclonal antibody that binds VEGF and inhibits binding to VEGFR, potentially resulting in decreased tumor growth (PMID: 15136787). Avastin (bevacizumab) is FDA approved for use in colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical carcinoma, and ovarian cancer, and in combination with carboplatin and paclitaxel in epithelial ovarian, fallopian tube, or primary peritoneal cancer (FDA.gov).|
|Niraparib||Zejula||MK4827||PARP Inhibitor (Pan) 29||Zejula (niraparib) binds to and inhibits PARP, which may result in the accumulation of DNA damage and apoptosis of tumor cells (PMID: 23810788). Zejula (niraparib) is FDA-approved for use as maintenance therapy in patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer in complete or partial response to first-line platinum-based chemotherapy, and as maintenance therapy in patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer harboring deleterious or suspected deleterious germline BRCA mutations and in complete or partial response to platinum-based chemotherapy (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT05523440||Phase II||Bevacizumab + Niraparib Niraparib||Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation (ARID1A)||Recruiting||USA||0|
|NCT03326193||Phase II||Bevacizumab + Niraparib||Phase 2, A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy||Active, not recruiting||USA||0|
|NCT05183984||Phase II||Carboplatin + Niraparib + Paclitaxel Bevacizumab + Carboplatin + Paclitaxel Bevacizumab + Niraparib||Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer (NIRVANA-1)||Recruiting||FRA||1|
|NCT02354131||Phase Ib/II||Niraparib Bevacizumab + Niraparib||Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian Cancer (AVANOVA)||Completed||USA||1|
|NCT05009082||Phase III||Carboplatin + Niraparib + Paclitaxel Bevacizumab + Niraparib Bevacizumab + Carboplatin + Paclitaxel||Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer||Recruiting||DEU||0|
|NCT05065021||Phase II||Bevacizumab + Dostarlimab-gxly + Niraparib Bevacizumab + Niraparib Bevacizumab + Dostarlimab-gxly + Paclitaxel||Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor||Recruiting||CAN||0|